文献速递创面修复显微修复重建

LymfactinⓇ联合淋巴结移植治疗上肢淋巴水肿的Ⅰ期安全性研究

Phase 1 LymfactinⓇ Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2020-05-18

该Ⅰ期研究将腺病毒5型介导的VEGF-C基因治疗(LymfactinⓇ)与微血管淋巴结移植联合,用于乳腺癌相关上肢淋巴水肿患者,评估安全性与耐受性。

要点

  • LymfactinⓇ联合淋巴结移植在12个月随访中耐受良好,未达剂量限制性毒性。
  • 常见不良事件包括感冒、发热、胃肠炎、术区疼痛、头痛、肌痛和肝酶升高。
  • 严重不良事件为淋巴水肿臂丹毒感染2例(需住院)和皮瓣供区血肿1例。

核心结论

  • 12个月随访结果表明LymfactinⓇ联合微血管淋巴结移植耐受良好。
  • 研究以预先确定的最大剂量完成,未观察到剂量限制性毒性。
  • 肿瘤学安全性需更长随访期评估。

研究设计与样本

  • Ⅰ期临床研究,LymfactinⓇ联合微血管淋巴结移植治疗上肢淋巴水肿。
  • 3例接受低剂量(1×10^10)病毒颗粒,12例接受高剂量(1×10^11)病毒颗粒。

主要发现

  • 未观察到剂量限制性毒性,研究以预定最大剂量完成。
  • 12个月随访常见不良事件包括感冒、发热、胃肠炎、术区疼痛、头痛、肌痛和肝酶升高。
  • 严重不良事件包括淋巴水肿臂丹毒感染2例(需住院)和皮瓣供区血肿1例。

临床怎么用

  • LymfactinⓇ联合淋巴结移植在Ⅰ期研究中显示可耐受的安全性特征。
  • 需关注淋巴水肿臂感染和皮瓣供区血肿等严重不良事件。
  • 肿瘤学安全性尚需长期随访确认。

局限性

  • 随访期短(12个月),疗效与长期安全性待36个月疗效和5年安全性随访。
  • 肿瘤学安全性需更长随访期评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the safety and tolerability of LymfactinⓇ treatment combined with microvascular lymph node transfer surgery in patients with upper limb lymphedema. BACKGROUND: Upper limb lymphedema is a common clinical challenge after breast cancer surgery and/or radiotherapy. LymfactinⓇ is an adenovirus type 5-based gene therapy involving expression of human vascular endothelial growth factor C (VEGF-C) in the damaged tissue. It aims to correct deficient lymphatic flow by promoting the growth and repair of lymphatic vessels. METHODS: In Phase I, LymfactinⓇ was combined with microvascular lymph node transfer surgery to study the safety and tolerability of LymfactinⓇ and the biodistribution of the viral vector in patients with upper limb lymphedema. RESULTS: Fifteen patients with breast cancer-associated secondary lymphedema of the upper arm were recruited between December 2016 and February 2018. Three patients received a lower dose (1 × 1010) and 12 a higher dose (1 × 1011) of viral particles, respectively. No dose-limiting toxicities were observed, and the study was completed with the pre-determined maximum dose. Commonly reported adverse events during the 12-month follow-up were common cold, fever, gastroenteritis, pain in the operation area, headache, muscle ache and elevated liver enzymes. Serious adverse events consisted of two erysipelas infections in the lymphedema arm (requiring hospitalization) and one hematoma of the flap donor site. CONCLUSIONS: After 12 months' follow-up, results indicate that LymfactinⓇ is well tolerated. The study continues with a 36-months efficacy and 5 years safety follow-up of the patients. The oncological safety aspects of LymfactinⓇ will require a longer follow-up period.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Hartiala P, Suominen S, Suominen E, et al. Phase 1 LymfactinⓇ Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema. J Plast Reconstr Aesthet Surg. 2020. PMID: 32513642. doi:10.1016/j.bjps.2020.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。